GRI Bio (GRI) Expected to Announce Quarterly Earnings on Thursday

GRI Bio (NASDAQ:GRI) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($6.80) per share for the quarter.

GRI Bio Stock Down 16.9 %

NASDAQ:GRI opened at $6.70 on Wednesday. The business’s 50-day simple moving average is $8.67 and its two-hundred day simple moving average is $10.61. GRI Bio has a 52 week low of $5.12 and a 52 week high of $176.80. The stock has a market cap of $3.52 million, a PE ratio of -0.58 and a beta of -2.10.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on GRI shares. Ascendiant Capital Markets increased their price target on GRI Bio from $204.00 to $221.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. HC Wainwright started coverage on GRI Bio in a research report on Monday, December 9th. They set a “buy” rating and a $170.00 target price for the company.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.